Transition readiness in adolescents with juvenile idiopathic arthritis and their parents: Our single-center experience

Dragana Lazarević 1,2, Stefan Đorđević 3, Dušica Novaković 4, Maja Zečević 5, Gordana Sušić 4

1Department of Pediatric Rheumatology, Clinic of Pediatrics, University Clinical Center, Niš, Serbia
2Faculty of Medicine, University of Niš, Niš, Serbia
3Department of Cardiology and Rheumatology, University Children’s Hospital, Belgrade, Serbia
4Department of Pediatric Rheumatology, Institute of Rheumatology, Belgrade, Serbia
5Department of Pediatric Surgery, Clinic For Pediatric Surgery and Orthopedics, University Clinical Center, Niš, Serbia

ABSTRACT

Objectives: We aimed to identify characteristics of juvenile idiopathic arthritis (JIA) patients associated with good self-management skills in the transition readiness process and to investigate the readiness of JIA patients and their families for the transition into the adult healthcare system.

Patients and methods: Between March 2021 and June 2021, a total of 44 JIA patients (9 males, 35 females; median age: 15.1 years; range, 12.3 to 19.3 years) admitted to the pediatric rheumatology outpatient and inpatient clinics and their parents were included. Transition Readiness Assessment Questionnaire (TRAQ) was cross-culturally adapted. The TRAQ was administered to all JIA patients and their parents at one point. Demographic and clinical data were collected.

Results: Fourteen (31.8%) of 44 JIA patients had a concomitant disease, while 10 (22.7%) of them had uveitis. Eleven (25%) of them had a family history of autoimmune diseases. In total, 21 (47.7%) of JIA patients were receiving biologics. There was a strong correlation between older age and total TRAQ scores among patients (ρ=0.799, p<0.001) and a moderate correlation between older patient age and total TRAQ scores among parents (ρ=0.522, p<0.001). Patient and parent total TRAQ scores were strongly correlated (ρ=0.653, p<0.001). There was no significant association of JIA patient characteristics (JIA disease subtypes, disease duration, gender, concomitant diseases, uveitis, family history of autoimmune diseases, number of hospitalizations, and treatment with biologics) with TRAQ scores and JIA patients’ and parents’ readiness for transition.

Conclusion: Transition readiness of JIA patients increases with advancing age. There is no significant difference between transition readiness for JIA patients and their parents.

Keywords: Adolescents, juvenile idiopathic arthritis, transition readiness assessment, Transition Readiness Assessment Questionnaire.

Healthcare transition is defined as purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented healthcare systems.1 This transfer from pediatric to adult healthcare represents a very vulnerable period for juvenile idiopathic arthritis (JIA) patients and their families. Juvenile idiopathic arthritis is a heterogeneous group of diseases that encompasses all forms of arthritis of unknown origin with onset before the age of 16 years.2 It is one of the most common childhood chronic rheumatic diseases that affects the quality of life of children and their families and causes much disability.3 Patients with this disease frequently need specialized treatments and psycho-emotional...
support during their lifetime. The critical moment for JIA patients is transition from pediatric to adult-oriented healthcare system. This complex process occurs over the time, while growing up, and is characterized by consolidation of personal identity, striving to gain complete independence from parents in decision making, establishing personalized communication skills, raising levels of responsibility, ability to make independent decisions related to their health, choosing professional orientation and family planning. To achieve responsibility for their own health, young individuals with JIA need to be provided with continuous medical and psychosocial support. Therefore, to enable optimal functioning of JIA patients in adulthood, it is necessary to provide continuous adapted care and treatment, through appropriate transition programs. Transitional programs should be individualized and adjusted to the national healthcare needs.

The latest recommendations of the European League Against Rheumatism (EULAR) and the Pediatric Rheumatology European Society (PReS) propose that transition would be more successful, if it starts as early as possible: from early adolescence (11 to 14 years) or directly after the diagnosis has been established. In our setting, transfer starts when young adults finish high school. First, we inform patients and their families of the necessity of continuous healthcare in adult oriented institutions. Then, we contact adult rheumatologists, familiarize them with the patient’s medical record, and arrange the patient transfer. Unfortunately, many studies have demonstrated unsuccessful transitional care of pediatric rheumatology patients. In practice, young adults with a stable disease often fail to attend their regular appointments with a rheumatologist, which results in a worse outcome of the disease. Lack of adult rheumatologists’ knowledge on transitional process, a high patient burden, decreased access to patient information, insufficient communication with pediatric rheumatologists, and the lack of parental supervision are additional barriers to the successful transition. Failure from pediatric to adult healthcare transition can lead to severe consequences such as joint damage, disability, increased number of hospitalizations, and impairment in the quality of life. Approximately 37 to 60% of young adults with JIA reach adulthood with active disease and functional disability. To avoid the occurrence of permanent disability, it is important to adequately educate and provide psycho-emotional support to JIA patients and their parents as early as possible by implementing the Six Core Elements of Healthcare Transition, including the assessment of transition readiness.

In the present study, we aimed to evaluate the characteristics of JIA patients that may lead to the improvement in self-management skills in the transition readiness process and to explore the readiness of JIA patients and their families for the transition process into the adult healthcare system.

**PATIENTS AND METHODS**

This single-center, cross-sectional study was conducted at Institute of Rheumatology, Department of Pediatric Rheumatology between March 2021 and June 2021. A total of 44 JIA patients (9 males, 35 females; median age: 15.1 years; range, 12.3 to 19.3 years) admitted to the pediatric rheumatology outpatient and inpatient clinics and their parents were included. The TRAQ was cross-culturally adapted. Demographic data and clinical characteristics, including JIA disease subtype, sex, age at the time of diagnosis, disease duration, disease activity, previous and current therapies, comorbidities,
family history of autoimmune diseases, number of hospitalizations, number of active joints, physician and parent/patient global assessment were obtained from the patients' medical records and physical examination. In this cross-sectional study, paper version of the TRAQ was administered to all JIA patients and their parents at one time point (the patients and parents filled in the questionnaires independently). We obtained blood samples for routine laboratory monitoring of drug treatment safety. Disease activity was evaluated using the Juvenile Disease Activity Score (JADAS 10, JADAS 27, JADAS 71).22-24

Statistical analysis

Statistical analysis was performed using the IBM SPSS version 20.0 software (IBM Corp., Armonk, NY, USA). Continuous data were expressed in median (min-max), while Categorical data were expressed in number and frequency. Categorical variables were compared using the chi-square test. The Mann-Whitney U test was used to compare continuous variables between two groups. The association between numeric variables was assessed using the Spearman rank correlation coefficient ($r_s$). A $p$ value of <0.05 was considered statistically significant.

RESULTS

Among 44 JIA patients, two (4.5%) had systemic JIA, 16 (36.4%) had oligoarticular/extended oligoarticular JIA, 15 (34.1%) had polyarticular JIA, 10 (22.7%) had enthesitis-related arthritis, and one (2.3%) had psoriatic JIA. Fourteen (31.8%) patients had a concomitant disease: two had Hashimoto thyroiditis, two had epilepsy, while 10 of them (22.7%) had uveitis. Eleven (25%) had a family history of autoimmune diseases. At the time TRAQ was administered, 19 (43.2%) patients had active arthritis, while 23 (52.3%) of JIA patients had active disease status according to the JADAS 10 and JADAS 27.

All patients were treated with diverse disease-modifying drugs: 32 (72.7%) patients were receiving methotrexate, 10 (22.7%) receiving sulfasalazine, and two (4.6%) receiving hydroxychloroquine. Twenty-six (59.1%) patients were treated with intra-articular corticosteroid injections, while 19 (43.2%) were taking oral prednisone. In total, 21 (47.7%) of JIA patients were receiving biologics; 12 were treated with tumor necrosis factor inhibitors (etanercept n=4; adalimumab n=8), and nine were receiving interleukin-6 (IL-6) inhibitors (tocilizumab). A detailed demographic and disease data are presented in Table 1.

There was a strong correlation between older patient age and total TRAQ score among patients ($r=0.799$, $p<0.001$) and a moderate correlation between older patient age and total TRAQ score among parents ($r=0.522$, $p<0.0001$). Patient and parent total TRAQ scores showed a strong correlation ($r=0.653$, $p<0.001$).

| Table 1. Demographic data of JIA patients (n=44) |
|------------------------------------------------|
| Characteristics                                   | n  | %     | Median | Range        |
| Age at JIA diagnosis (year)                       | 11.54 | 1.5-16.0        |
| Sex                                              |     |       |       |             |
| Female                                           | 35  | 79.5  |       |             |
| Male                                             | 9   | 20.5  |       |             |
| Age at the study enrolment (year)                | 15.12 | 12.33-19.33 |
| Median JIA duration (year)                       | 4.29 | 0.42-17.5     |
| Concomitant diseases                             | 14  | 31.8  |       |             |
| JIA associated uveitis                           | 10  | 22.7  |       |             |
| Family history of autoimmune diseases            | 11  | 25     |       |             |
| Duration of methotrexate treatment (year)        | 2.0  | 0-12.5 |       |             |
| Dose of methotrexate (mg/m²/week)                | 11.0 | 0-20.0 |       |             |
| Dose of corticosteroids (mg/day)                 | 5.80 | 0-30.0 |       |             |
| Patients receiving biologics                     | 21  | 47.7  |       |             |

JIA: Juvenile idiopathic arthritis.
There was no statistically significant association between JIA patient characteristics including JIA disease subtypes, sex, disease duration, disease activity, concomitant diseases including uveitis, family history of autoimmune diseases, number of hospitalizations and the use of biologics with total TRAQ score in both the patient and parent groups.

**DISCUSSION**

Children and young adults with JIA need to be supported in preparation for and during the transition period from the pediatric to adult healthcare system. To foster this challenging process, it is important to prepare them to be independent and responsible for their own health in adulthood. In 2002, the American Academy of Pediatrics (AAP) published recommendations for the successful transition. Additionally, EULAR and PReS developed standards and recommendations for successful transition of JIA patients in 2017. However, more than half of JIA patients still do not have a successful transition to the adult healthcare system. It is, therefore, important to identify potential indicators of successful transition. In this study, we explored the transition process of JIA patients and their parents using TRAQ to identify which patient characteristics might lead to the improvement in self-management skills in the transition readiness process. Our results revealed that total TRAQ scores among patients increased with increasing age, suggesting that older adolescents have higher levels of self-management skills than younger adolescents. This can be explained by increased responsibility that increases with age. Similar observations were reported by several authors. In contrast, Jensen et al. showed that the increase in TRAQ score was not associated with increasing age in patients with chronic health conditions. Sönmez et al. also reached the same conclusion. In our study, total TRAQ scores among parents also increased with increasing age and total TRAQ scores did not significantly differ between patients and parents. This might be explained by the fact that parents of children with chronic diseases are overprotective in caring for their children. Sönmez et al. also reported similar results.

Lazaroff et al. showed that sex may impact transition readiness and that female JIA patients had higher total TRAQ scores and better transition readiness than male patients. This is similar to the finding of Varty and Popejoy who studied the transition process in patients with various chronic diseases. Similar to our results, the other authors found no significant difference in total TRAQ scores between female and male JIA patients.

In contrast to our findings, Bingam et al. reported that having a concomitant disease, family member with autoimmune disease, and longer disease duration was associated with higher self-reported independence and transition readiness. We found no significant association between disease activity or number of previous hospitalizations and readiness for transition. As opposed to our findings, Turkish authors showed that active disease and the increasing number of previous hospitalizations were associated with lower TRAQ scores and the decreased readiness for transitional care. To the best of our knowledge, this is the first study to show that JIA disease subtypes, JIA associated uveitis, and treatment with biologics are not associated with TRAQ scores and JIA patients' and parents' readiness for transition.

This study was subject to some limitations, including the cross-sectional design, small sample size, short participant recruitment period, and the heterogeneous study sample.

In conclusion, our study results show that advancing age of JIA patients has a positive impact on patient's and parents' readiness for transition. It seems that both patients and their parents have the same capacity to accept the transition from a pediatric to adult rheumatologist. Future studies with a larger sample size and new insights are needed to facilitate this challenging transition process.

**Ethics Committee Approval:** The study protocol was approved by the Ethics Board of the Institute of Rheumatology, (No: 29/8, Date: 24/03/2021). The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Patient Consent for Publication:** A written informed consent was obtained from each patient.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions: All authors contributed equally to the article.

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding: The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. Blum RW, Garell D, Hodgman CH, Jorissen TW, Okinow NA, Orr DP, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolesc Health 1993;14:570-6.

2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:2138-49.

3. Martini A, Lovell DJ. Juvenile idiopathic arthritis: State of the art and future perspectives. Ann Rheum Dis 2010;69:1260-3.

4. McColl J, Semalulu T, Beattie KA, Alam A, Thomas S, Herrington J, et al. Transition readiness in adolescents with juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. ACR Open Rheumatol 2021;3:260-5.

5. Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S, et al. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 2017;76:639-46.

6. Bingham CA, Scalzi L, Grob B, Boehmer S, Banks S. An assessment of variables affecting transition readiness in pediatric rheumatology patients. Pediatr Rheumatol Online J 2015;13:42.

7. Sabbagh S, Ronis T, White PH. Pediatric rheumatology: Addressing the transition to adult-oriented health care. Open Access Rheumatol 2018;10:83-95.

8. Spiegel L, Tucker L, Duffy KW, Lalloo C, Hundert A, Bourre-Tessier J, et al. Development and validation of the RACER (Readiness for Adult Care in Rheumatology) transition instrument in youth with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2021;19:83.

9. Costagliola G, Mosca M, Migliorini P, Consolini R. Pediatric systemic lupus erythematosus: Learning from longer follow up to adulthood. Front Pediatr 2018;6:144.

10. Dimopoulou D, Trachana M, Pratsidou-Gertsii P, Sidiropoulos P, Kanakoudi-Tsakalidou F, Dimitroulas T, et al. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: A 17-year continuous follow-up study. Rheumatology (Oxford) 2017;56:1928-38.

11. Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long-term outcomes in juvenile idiopathic arthritis: Eighteen years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res (Hoboken) 2020;72:507-16.

12. Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2019;71:290-301.

13. Hersh A, von Scheven E, Yelin E. Adult outcomes of childhood-onset rheumatic diseases. Nat Rev Rheumatol 2011;7:290-5.

14. Sanner H, Sjaastad I, Flaato B. Disease activity and prognostic factors in juvenile dermatomyositis: A long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 2014;53:1578-85.

15. Hazel E, Zhang X, Duffy CM, Campillo S. High rates of unsuccessful transfer to adult care among young adults with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2010;8:2.

16. Selvaag AM, Aulie HA, Lillevy V, Flaato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2016;75:190-5.

17. Kittivisuit S, Lerkvaleekul B, Soponkanaporn S, Ngamjanyaporn P, Vilaiyuk S. Assessment of transition readiness in adolescents in Thailand with rheumatic diseases: A cross-sectional study. Pediatr Rheumatol Online J 2021;19:101.

18. Clemente D, Leon L, Foster H, Minden K, Carmona L. Systematic review and critical appraisal of transitional care programmes in rheumatology. Semin Arthritis Rheum 2016;46:372-9.

19. Sawicki GS, Lukens-Bull K, Yin X, Demars N, Huang IC, Livingood W, et al. Measuring the transition readiness of youth with special healthcare needs: Validation of the TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr Psychol 2011;36:160-71.

20. Wood DL, Sawicki GS, Miller MD, Smotherman C, Lukens-Bull K, Livingood WC, et al. The Transition Readiness Assessment Questionnaire (TRAQ): Its factor structure, reliability, and validity. Acad Pediatr 2014;14:415-22.

21. Chan JT, Soni J, Sahni D, Mantis S, Boucher-Berry C. Measuring the transition readiness of adolescents with type 1 diabetes using the transition readiness assessment questionnaire. Clin Diabetes 2019;37:347-52.

22. Consolaro A, Ruperto N, Bazo A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score.

Transition readiness of JIA patients
for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.

23. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol 2012;30(4 Suppl 73):S157-62.

24. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366-74.

25. Ardoin SP. Transitions in rheumatic disease: Pediatric to adult care. Pediatr Clin North Am 2018;65:867-83.

26. Hersh AO, Pang S, Curran ML, Milojevic DS, von Scheven E. The challenges of transferring chronic illness patients to adult care: Reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J 2009;7:13.

27. McDonagh JE. Transition of care from paediatric to adult rheumatology. Arch Dis Child 2007;92:802-7.

28. Lazaroff SM, Meara A, Tompkins MK, Peters E, Ardoin SP. How do health literacy, numeric competencies, and patient activation relate to transition readiness in adolescents and young adults with rheumatic diseases? Arthritis Care Res (Hoboken) 2019;71:1264-9.

29. Jensen PT, Paul GV, LaCount S, Peng J, Spencer CH, Higgins GC, et al. Assessment of transition readiness in adolescents and young adults with chronic health conditions. Pediatr Rheumatol Online J 2017;15:70.

30. Sönmez HE, Koç R, Karadağ SG, Aktay Ayaz N. The readiness of pediatric rheumatology patients and their parents to transition to adult-oriented treatment. Int J Rheum Dis 2021;24:397-401.

31. Varty M, Popejoy LL. A systematic review of transition readiness in youth with chronic disease. West J Nurs Res 2020;42:554-66.